BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29220877)

  • 21. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
    Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
    Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters.
    Gupta L; Suku P; Dash A; Bose P; Sharma P; Mallik N; Sreedharanunni S; Varma N; Jandial A; Malhotra P; Sachdeva MUS
    Curr Probl Cancer; 2024 Feb; 48():101025. PubMed ID: 37951052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells.
    Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Ikemoto T; Tanaka H; Nishimura Y; Tsuji M; Hanafusa T
    Diagn Pathol; 2012 Sep; 7():131. PubMed ID: 23021410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
    Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
    Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
    An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
    Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression.
    Gonsalves WI; Rajkumar SV; Dispenzieri A; Dingli D; Timm MM; Morice WG; Lacy MQ; Buadi FK; Go RS; Leung N; Kapoor P; Hayman SR; Lust JA; Russell SJ; Zeldenrust SR; Hwa L; Kourelis TV; Kyle RA; Gertz MA; Kumar SK
    Leukemia; 2017 Jan; 31(1):130-135. PubMed ID: 27457702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging flow cytometric detection of del(17p) in bone marrow and circulating plasma cells in multiple myeloma.
    Mincherton TI; Lam SJ; Clarke SE; Hui HYL; Malherbe JAJ; Chuah HS; Sidiqi MH; Fuller KA; Erber WN
    Int J Lab Hematol; 2024 Jun; 46(3):495-502. PubMed ID: 38379463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Blood Cancer J; 2016 Dec; 6(12):e512. PubMed ID: 27983726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies.
    Tembhare PR; Ghogale S; Tauro W; Badrinath Y; Deshpande N; Kedia S; Cherian K; Patkar NV; Chatterjee G; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2018 May; 94(3):509-519. PubMed ID: 29316178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
    Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
    Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
    Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new staging system for multiple myeloma based on the number of S-phase plasma cells.
    San Miguel JF; García-Sanz R; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
    Blood; 1995 Jan; 85(2):448-55. PubMed ID: 7811998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
    Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
    Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
    Kim D; Park CY; Medeiros BC; Weissman IL
    Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The immunophenotypic stability of plasma cell myeloma by flow cytometry.
    Spears MD; Olteanu H; Kroft SH; Harrington AM
    Int J Lab Hematol; 2011 Oct; 33(5):483-91. PubMed ID: 21470371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an unbiased, semi-automated approach for classifying plasma cell immunophenotype following multicolor flow cytometry of bone marrow aspirates.
    Post SR; Post GR; Nikolic D; Owens R; Insuasti-Beltran G
    Cytometry B Clin Cytom; 2018 Sep; 94(5):602-610. PubMed ID: 29573142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
    Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
    Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunophenotyping of plasma cells.
    Rawstron AC
    Curr Protoc Cytom; 2006 May; Chapter 6():Unit6.23. PubMed ID: 18770841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma.
    Popov A; Druy A; Shorikov E; Verzhbitskaya T; Solodovnikov A; Saveliev L; Tytgat GAM; Tsaur G; Fechina L
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):535-542. PubMed ID: 30603901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study.
    Limvorapitak W; Srisum-Ang T; Chimres C; Warnnissorn N; Kanitsap N
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):e27-37. PubMed ID: 26796980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.